Obtaining approval for a phase 1 clinical trial in patients with hepatocellular carcinoma

Current report no. 43/2024

Drafting date: 18 December 2024

Subject: Obtaining approval for a phase 1 clinical trial in patients with hepatocellular carcinoma

Legal basis: Article 17(1) MAR - confidential information.

In reference to current report No. 31/2024 dated 22 August 2024 regarding the submission of an application to the European Medical Agency (EMA) for permission to conduct a first-in-human Phase 1 clinical trial of the compound CT-01, the Management Board of Captor Therapeutics S.A., based in Wrocław (the ‘Company’),  has received the approval of the trial, subject to specified changes being made to the protocol, data safety monitoring board, and informed consent form, from all three countries involved. The study will begin once the amended documents have been reviewed by the regulators.

The Company will inform of conduct of clinical trials as required by law.